Journal Logo

Articles

Minoxidil Inhibits Proliferation and Migration of Cultured Vascular Smooth Muscle Cells and Neointimal Formation After Balloon Catheter Injury

Li, Zhihe; Nater, Cynthia; Kinsella, James; Chrest, Francis; Lakatta, Edward G.

Author Information
Journal of Cardiovascular Pharmacology: August 2000 - Volume 36 - Issue 2 - p 270-276
  • Free

Abstract

The response of the vascular wall to mechanical injury resulting in the formation of an occlusive intimal lesion is the major complication of invasive vascular procedures, including percutaneous transluminal coronary angioplasty (1-4) and coronary bypass grafting (5,6). Smooth muscle cell (SMC) proliferation and migration are characteristic of the neointimal lesion formed after mechanical injury to the vessel wall (7,8). Reduction of SMC proliferation and migration may reduce the restenotic lesion after the vascular injury. Despite a variety of attempts with pharmacologic interventions and instrument techniques, restenosis after mechanical injury to the vessel wall remains a problem (9).

Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide, I) is a potent vasodilator and therefore has been used to reduce the blood pressure. The antihypertensive activity of minoxidil results from a decrease in peripheral resistance, due primarily to direct relaxation of SMCs (10-12). In some in vitro studies, minoxidil suppressed keratinocyte growth and human lymphocyte activities (13,14). An antiproliferative effect of minoxidil also has been observed in SMCs from chick aorta (15). However, the effect of minoxidil on SMC migration and its significance in inhibition of vascular lesions was poorly understood. Our studies examined the effects of minoxidil on SMC migration and proliferation in vitro and on neointimal formation in vivo after vascular injury.

MATERIALS AND METHODS

Reagents

Minoxidil (U-10858) was generously provided by Pharmacia-Upjohn, Inc. (Kalamazoo, MI, U.S.A.). A stock solution containing 1% minoxidil for tissue culture was prepared by dissolving minoxidil in 20% ethanol. For in vivo studies, minoxidil was dissolved in tap water in the concentrations of 120 mg/L and 200 mg/L plus 250 mg/L of sodium hydrochlorothiazide, respectively (Sigma, St. Louis, MO, U.S.A.). Platelet-derived growth factor-BB (PDGF-BB) was purchased from R&D Systems (Minneapolis, MN, U.S.A.).

Tissue culture

Male Wistar rats, aged 6 months, were killed by an overdose of sodium pentobarbital, and aortae, including thoracic and abdominal portions, were removed under sterile conditions. After rinsing several times in antibiotic-containing Hank's balanced salt solution (Gibco, Grand Island, NY, U.S.A.), the vessel was opened longitudinally, and the adventitia and intima were carefully removed. SMC cultures were established using the technique described previously (16). In brief, tissues were cut into small pieces and placed into 60-mm petri dishes with Dulbecco's Modified Eagle's Medium (DMEM; Gibco) containing 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin, 100 μg/ml of streptomycin, 20 mM L-glutamine, 1 mM nonessential amino acids, 0.1 μg/ml amphotericin B, and 0.08 μg/ml sodium deoxycholate. Cells were detached by incubation with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) solution and reseeded for subcultures. The explants, and subsequently cells, were cultured in an incubator at 37°C, in 5% carbon dioxide and 95% air. Cells were fed twice a week with fresh culture medium. Third and fourth passage SMCs, verified by positive staining of α-smooth muscle actin, were used in this study.

Flow cytometry

SMCs were seeded at a density of 1.5 × 106 and fed with DMEM containing 10% FBS followed by serum-starvation for 48 h. The culture medium was replaced by medium containing 10% FBS and 0.24, 0.48, 0.96, 1.91, and 3.82 mM minoxidil for 18 h. The medium containing vehicle alone was used in the control group. Cells were detached by incubation with 0.25% trypsin, washed with PBS containing 1% bovine serum albumin, and fixed with 100% ethanol at 4°C for 1 h. After washing with PBS containing 1% bovine serum albumin, cells were treated with DAPI solution. The distribution of SMCs in different phases of the cell cycle was analyzed according to their DNA content determined by a flow cytometer. The distribution of cells in the cell cycle was calculated as the average of that from three different preparations of SMCs from a pooled cell line.

Migration assay

A modified Boyden chamber assay, as described elsewhere (17,18), was used for evaluation of SMC migration. In brief, PVPF filters with 8-mm pores (Nucleopore filters, Cambridge, MA, U.S.A.) were coated with 50 μl collagen I (100 μg/ml). The coated filter was allowed to dry overnight at room temperature. DMEM containing 100 ng/ml of PDGF-BB, as a chemoattractant, was loaded into the lower chamber. The coated filter then was placed into the Boyden chamber to separate the upper from the lower chamber. Serum-starved SMCs suspended in the media containing 0.01, 0.05, and 1.25 mg/ml of minoxidil were loaded into the upper chamber (final volume of 800 μl of cell suspension containing 2 × 105 cells). SMCs suspended in DMEM containing vehicle alone were used as the control. The chambers were placed in an incubator for 4 h at 37°C in 5% carbon dioxide and 95% air. The filters were removed from the chambers and fixed by HEMA fixative solution (Curtin Matheson Scientific Inc., Houston, TX, U.S.A.). Hematoxylin and eosin solutions (HEMA) were used to stain the cells that had migrated toward the chemoattractant and were attached to the lower side of the filter. From each filter, the cell number in eight adjacent fields was counted under a light microscope (×100), and the average was taken to represent the number of migrated cells. Five filters were counted from each group. The migration assay was repeated 3 times with different SMC preparations from the pooled cell lines.

Minoxidil treatment and vascular injury

Twenty-eight male, 4-month-old Wistar rats (300 g) were randomly divided into three groups. A group of rats (n = 8) received minoxidil, 120 mg/L in their drinking water. Another group of rats (n = 10) received drinking water containing 200 mg/L minoxidil. In both concentrations, 250 mg/L of sodium hydrochlorothiazide was added to minimize sodium and water retention, side effects of minoxidil (19). A group of 10 rats, given tap water without minoxidil, served as controls. In a separate group of rats (n = 5), the carotid arteries were injured, and minoxidil (200 plus 250 mg/L sodium hydrochlorothiazide) was given in the drinking water from days 1 to 14 after vascular injury. All animals were fed with normal rat chow and tap water or minoxidil-containing water ad libitum for 3 weeks before vascular injury. The animal care complied with the "Principles of Laboratory Animal Care (formulated by the National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23, revised 1985).

Vascular injury was effected by the technique described by Clowes et al. (20). In brief, rats were anesthetized by intraperitoneal injection with 40 mg/kg of sodium pentobarbital and 8 mg/kg of xylazine. The left carotid artery was surgically separated, and a small incision was made on the external carotid artery with ophthalmologic scissors. A 2F Fogarty arterial embolectomy balloon catheter (Baxter, McGraw Park, IL, U.S.A.) was inserted through the incision in the external carotid artery into the common carotid artery. The catheter was inflated with 30 μl of saline and withdrawn along the common carotid artery. The effective passing distance of the balloon catheter was 2.5-3.0 cm (i.e., the entire length of the common carotid artery). The ballooning procedure was repeated 3 times to ensure a complete endothelial denudation. The external carotid artery was ligated, and the animals were allowed to recover. Minoxidil-treated groups continued to receive minoxidil in their drinking water for another 2 weeks after surgery.

Morphometry

Animals were killed by an overdose of sodium pentobarbital, and 4% neutralized formalin was infused into the circulation for in situ fixation. The infusion pressure was maintained constantly at 100 mm Hg. Morphometric evaluation was carried out with a computerized imaging analysis system equipped with an Axioplan microscope (Zeiss, Germany) and a black-and-white MTI video camera (Dage-MTI Inc.). Video images were enhanced by normalization and dynamic thresholding and analyzed by IBAS 2.0 software (IBAS, Kontron Elektronik).

For determination of neointimal area, images were acquired from Movat pentachrome-stained slides under ×100 magnification. The neointimal area was defined as that between the internal elastic lamina and the lumen surface. Five images were obtained from different segments harvested from each injured artery, and the average was taken to represent the neointimal area of the vessel. The average neointimal area was calculated from each group and compared statistically among the groups. All the morphometric measurements were carried out by individuals blinded as to the drug treatment each rat received.

Statistical analysis

Data are presented as mean ± standard error of the mean. Distribution of SMCs in the cell cycle was analyzed by one-way analysis of variance (ANOVA). All other data were statistically analyzed by one-way ANOVA followed by Tukey's Honest Significant Difference (HSD) test for multiple comparisons. Significance was considered only when the p value was <0.05.

RESULTS

Minoxidil inhibits SMC proliferation and migration

SMCs were allowed to reach a quiescent stage by incubation in a serum-starved state for 48 h. The culture media was then switched to DMEM containing 10% fetal bovine serum. SMCs in the control group started to grow and nearly reach confluence in the culture dish (Fig. 1A). However, the density of SMCs cultured with minoxidil-containing media was greatly reduced. The reduction of SMC density caused by minoxidil was concentration dependent (Fig. 1 B-F). No evidence of toxicity was observed after treatment with any the concentrations of minoxidil.

FIG. 1
FIG. 1:
Phase-contrast microphotographs of smooth muscle cells (SMCs) in culture with or without treatment of minoxidil.A: Control: SMCs incubated with DMEM containing 10% FBS. B-E: SMCs treated with 100 μg/ml (B), 200 μg/ml (C), 400 μg/ml (D), and 800 μg/ml (E) of minoxidil. The cell density decreased in a graded fashion with increasing minoxidil concentration (×200).

Minoxidil altered the distribution of SMCs in various phases of the cell cycle. In the absence of minoxidil, an average of 64.13% SMCs distributed in the G1 phase, 12.87% in the G2 phase, and 23% in the S phase (Fig. 2). In a concentration-related manner, minoxidil increased the number of SMCs in G1 and G2 phases and decreased the number of SMCs in S phase (Fig. 2). Low concentrations of minoxidil (0.24 mM) did not affect the cell-cycle distribution of the SMCs, whereas 3.82 mM minoxidil significantly increased the number of SMCs that remained in G1 phase and reduced the number of SMCs in S phase.

FIG. 2
FIG. 2:
Cell-cycle distribution of smooth muscle cells in the presence (solid symbols) and absence (open symbols) of minoxidil. Notice the gradual increase in SMC number in the G1 phase and decrease in SMC number in the S phase after treatment with increasing concentrations of minoxidil. Symbols and error bars indicate mean ± SEM of single measurements from three preparations.

An inhibitory effect of minoxidil on SMC migration was observed in the modified Boyden chamber assay. Minoxidil-induced inhibition of SMC migration was dose dependent (Fig. 3): the number of SMCs that migrated was reduced 13.5% by 0.01 mg/ml of minoxidil (p < 0.05); 16.8% by 0.05 mg/ml (p < 0.01); 40.47% by 0.25 mg/ml (p < 0.001); and 65.87% by 1.25 mg/ml (p < 0.001) of minoxidil added to the medium.

FIG. 3
FIG. 3:
Migration assay of smooth muscle cells in the presence and absence of minoxidil. The data represent the average number of SMCs that migrated through type I collagen membrane per microscopic field (×100). Minoxidil, in a dose-dependent pattern, inhibits SMC migration toward platelet-derived growth factor-BB. Bars represent the mean ± SEM of single determinations in each of three experiments.

Minoxidil reduced injury-induced neointimal lesions

Injury-induced neointimal formation is initiated from the penetration of blood-borne growth factors through the denuded intima into the media. Stimulated by these growth factors, the medial SMCs enter the cell cycle 1-3 days after the vascular injury (21). Although the SMCs continue to proliferate above basal levels for up to months, the peak of SMC proliferation occurs between 10 and 14 days, resulting in neointimal mass formation (22). In our study, animals received minoxidil in their drinking water. In both minoxidil-treated groups, the daily water consumption was 40-60 ml per rat. Therefore, the amount of minoxidil received by each rat was 16-24 mg/kg/day (120 mg/L) and 26-40 mg/kg/day (200 mg/L), respectively.

The vessels from both minoxidil-treated and control groups were harvested 14 days after injury (Fig. 4). In the carotid artery of control rats, an extensive neointimal lesion had formed by this time. The area of neointimal lesion was significantly reduced by both 120 and 200 mg/L of minoxidil treatment (Fig. 5). Treatment with 120 or 200 mg/L of minoxidil reduced the neointimal lesion by 37% (p < 0.01) and 44% (p < 0.001), respectively (Fig. 6). In the group of rats that received minoxidil treatment from days 1-14 after vascular injury, the area of neointima was not different compared with the control group (data not shown).

FIG. 4
FIG. 4:
Neointima formed after injury to control rats(A) and in rats receiving 120 mg/L (B) and 200 mg/L (C) of minoxidil. Notice the similar ratio of cell to matrix in the neointima of three groups of rats (H&E staining, magnification ×400).
FIG. 5
FIG. 5:
Comparison of the neointima of carotid arteries harvested from control(A) and minoxidil-treated rats (B, C). The neointima was reduced by the treatment with both 120 mg/L and 200 mg/L minoxidil (Movat pentochrome, ×100).
FIG. 6
FIG. 6:
Morphometric analysis of neointimal area in injured vessels. The neointimal area was significantly reduced by the treatment with minoxidil (p < 0.01 in both cases). Bars represent mean ± SEM of neointimal area (n = 8-10).

DISCUSSION

SMC proliferation and migration are the major factors that contribute to neointimal lesion formation in fibroproliferative vascular diseases, such as restenosis and atherosclerosis (7,8). Strategies to suppress SMC proliferation and migration therefore facilitate the reduction of vascular lesions. Our study demonstrates, for the first time, that minoxidil is an agent that can effectively reduce SMC migration and division. Evidence for this was observed both in vitro (i.e., the inhibitory effect of minoxidil on SMC proliferation and migration), as well as in vivo on the formation of neointimal lesion after mechanical injury to the vessel wall.

The mechanism by which minoxidil inhibits SMC proliferation and migration remains unclear. However, it has been found that minoxidil stimulates elastin synthesis in chick embryonic vascular SMCs (15) and also enhances the mRNA of lysyl oxidase, an extracellular enzyme that contributes to cross-linking of collagen and elastin in the extracellular matrix (23-25). Resultant changes in the extracellular matrix effected by minoxidil may inhibit or limit SMC proliferation and migration. Minoxidil is also an SMC relaxant that causes vasodilation. It acts as a K+ channel agonist to enhance K+ permeability, which results in decrease of cytoplasmic free Ca2+ concentration (26,27). A recent study has shown that intracellular Ca2+ concentration is a key factor in the ability of SMCs to migrate across a type I collagen membrane toward PDGF-BB (28). The inhibitory effect of minoxidil on SMC migration observed in our study may be due, at least partly, to a reduction in intracellular Ca2+ concentration. Furthermore, because minoxidil was found as a potential immunosuppressive agent (14), immunosuppressive activity of minoxidil might also contribute to the inhibition of SMC proliferation and migration, as well as neointimal formation after vascular injury.

Administration of minoxidil in drinking water has been previously used in long-term (10 weeks) treatment of high blood pressure in the spontaneously hypertensive rats (29). In our study, ≤200 mg/L of minoxidil was given to rats in drinking water for 5 weeks, and the maximal amount of minoxidil was 26-40 mg/kg/day. No evidence of toxicity was observed in the rats treated with minoxidil. It has been reported that rats safely received 30 mg/kg of minoxidil for a year (30). In addition, it has been noticed that minoxidil may induce sodium and fluid retention, as a side effect (31,32). The degree of sodium and water retention correlates with dose and time of administration of minoxidil, and also is related to the degree of impairment of renal function (19). To avoid such side effects, in our study and others (12,28), sodium hydrochlorothiazide, a diuretic agent, has been given along with the administration of minoxidil. Tsoporis et al. (33) have shown that minoxidil alone increased the medial area of the superior mesenteric artery in normotensive rats, but this increase was prevented by the combination of hydrochlorothiazide and minoxidil. This result suggests that the use of hydrochlorothiazide has been necessary to nullify minoxidil-induced abnormal alterations in the vessel wall. Future experiments may be required to determine the role of hydrochlorothiazide in SMC proliferation and migration, as well as whether the diuretic alone affects neointimal formation after balloon injury.

Minoxidil induces directly relaxation of smooth muscle; therefore it reduces vascular tone and lowers blood pressure (10-12). In this study, the blood pressure was not measured. However, any significant hemodynamic changes caused by minoxidil might have contributed to the diminished neointimal proliferative response, and thus might also be a mechanism of minoxidil-induced decrease in neointimal formation observed in our study.

Minoxidil treatment from days 1-14 after injury did not inhibit the neointimal formation. The major reason was probably that, in this regimen, minoxidil did not achieve concentration within the vessel wall that could effectively inhibit SMC proliferation and migration; thus pretreatment with minoxidil was used.

In summary, the presence of minoxidil in culture medium inhibits the proliferation and migration of vascular SMCs. Minoxidil also reduces the area of neointimal lesion formed after mechanical injury to the vessel wall. The antiproliferative and migratory effects of minoxidil suggest a new application for this agent (i.e., to reduce the extent of neointimal lesion formation in vascular diseases, especially restenosis after angioplasty).

REFERENCES

1. Mabin TA, Holmes DR, Smith HC, et al. Follow up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation 1985;71:754-60.
2. Roubin GS, Douglas JS Jr, King SB III. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty: a prospective randomized study. Circulation 1988;78:557-65.
3. Fishman RF, Kuntz RE, Carrozza JP Jr, et al. Long-term results of directional coronary atherectomy: predictors of restenosis. J Am Coll Cardiol 1992;20:1101-10.
4. Garratt KN, Holmes DR Jr, Bell MR. Restenosis after directional coronary atherectomy: differences between primary atheromatous and restenosis lesions and influence of subintimal tissue resection. J Am Coll Cardiol 1990;16:1665-71.
5. FitzGibbon GM, Leach AJ, Kafka HP, Keon WJ. Coronary bypass graft fate: long-term angiographic study. J Am Coll Cardiol 1991;17:1075-80.
6. Bourassa MG. Fate of venous grafts: the past, the present and the future. J Am Coll Cardiol 1991;17:1081-3.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
8. Clowes AW. Pathobiology of arterial healing. In: Strandness DE, Didisheim P, Clowes AW, Watson JT, eds. Vascular diseases: current research and clinical applications. New York: Grune & Stratton, 1987:351.
9. Gottsauner-Wolf M, Moliterno DJ, Lincoff AM, Topol EJ. Restenosis: an open file. Clin Cardiol 1996;19:347-56.
10. Du Charme DW, Freyburger WA, Graham BE, Carlson RB. Pharmacologic properties of minoxidil: a new hypotensive agent. J Pharmacol Exp Ther 1973;184:662-70.
11. Gilmore E, Weil J, Chidsey C. Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockage. N Engl J Med 1970;282:521-37.
12. Tsoporis J, Fields N, Lee RMKW, Leenen FHH. Effect of the arterial vasodilator minoxidil on cardiovascular structure and sympathetic activity in spontaneously hypertensive rats. J Hypertens 1993;11:1337-45.
13. O'Keefe E, Payne RE Jr. Minoxidil: inhibition of proliferation of keratinocytes in vitro. J Invest Dermatol 1991;97:534-6.
14. Galbraith GMP, Thiers BH. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol 1985;24:249-51.
15. Hayashi A, Suzuki T, Wachi H, et al. Minoxidil stimulates elastin expression in aortic smooth muscle cells. Arch Biochem Biophys 1994;315:137-41.
16. Li Z, Alavi MZ, Moore S. The proliferation of neointimal smooth muscle cells cultured from rabbit aortic explants after deendothelialization by a balloon catheter. Int J Exp Pathol 1994;75:169-77.
17. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
18. Li Z, Cheng H, Lederer WJ, Froehlich J, Lakatta EG. Enhanced proliferation and migration and altered cytoskeletal protein in early passage smooth muscle cells from young and old rat aortic explants. Exp Mol Pathol 1997;64:1-11.
19. Ryan JR, Jain AK, McMahon FG. Minoxidil treatment of severe hypertension. Curr Ther Res 1975;17:55-66.
20. Clowes AW, Reidy M, Clowes MM. Kinetics of cellular proliferation after arterial injury: smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33.
21. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985;56:139-45.
22. Webster WS, Bishop SP, Geer JC. Experimental aortic intimal thickening. I. Morphology and source of intimal cells. Am J Pathol 1974;76:245-64.
23. DuCharme DW, Freyburger WA, Graham BE, Carlsone RG. Pharmacologic properties of minoxidil: a new hypotensive agent. J Pharmacol Exp Ther 1973;184:662-70.
24. Yeowell HN, Marshall MK, Walker LC, Ha V, Pinnell SR. Regulation of lysyl oxidase mRNA in dermal fibroblasts from normal donors and patients with inherited connective tissue disorders. Arch Biochem Biophys 1994;308:299-305.
25. Kagan HM. In: Mecham RP, ed. Characterization and regulation of lysyl oxidase. In: Biology of extracellular matrix: a series regulation of matrix accumulation. Vol 1. Orlando, FL: Academic Press, 1986:321-98.
26. Meisheri KD, Cipkus LA. Biochemical mechanisms by which minoxidil sulfate influences mammalian cells. Dermatologica 1987;175(suppl 2):3-11.
27. Meisheri KD, Oleynek JJ, Puddington L. Role of protein sulfation in vasodilataion induced by minoxidil sulfate, a K+ channel opener. J Pharmacol Exp Ther 1991;258:1091-7.
28. Rozanski DJ, Lakatta EG, Sollott SJ. Chemoattractant-gradient-specific Ca2+-signaling regulates vascular myocyte chemotaxis. Circulation 1996;94(suppl 1):I-354.
29. Tsoporis J, Leenen FHH. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension 1988;11:376-86.
30. Carlson RG, Feenstra ES. Toxicologic studies with the hypotensive agent minoxidil. Toxicol Appl Pharmacol 1977;39:1-11.
31. Hammond JJ, Kirkendall WM. Minoxidil therapy for refractory hypertension and chronic renal failure. South Med J 1979;72:1429-32.
32. Larochelle P, Hamet P, Neroniade V, Kuchel O. Minoxidil in severe hypertension. Eur J Clin Pharmacol 1978;14:1-5.
33. Tsoporis J, Fields N, Lee RM, Leenen FHH. Arterial vasodilation and cardiovascular structural changes in normotensive rats. Am J Physiol 1991;260:H1944-52.
Keywords:

Smooth muscle cell; Minoxidil; Neointima; Migration

© 2000 Lippincott Williams & Wilkins, Inc.